ISIN | LU2041625653 |
---|---|
Valor Number | 49473275 |
Bloomberg Global ID | |
Fund Name | JSS Sustainable Equity - Future Health C USD acc |
Fund Provider |
J. Safra Sarasin Investmentfonds AG
Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com |
Fund Provider | J. Safra Sarasin Investmentfonds AG |
Representative in Switzerland |
J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00 |
Distributor(s) |
Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). |
Peculiarities |
Current Price * | 121.81 USD | 10.02.2025 |
---|---|---|
Previous Price * | 121.81 USD | 07.02.2025 |
52 Week High * | 131.39 USD | 30.08.2024 |
52 Week Low * | 114.58 USD | 18.04.2024 |
NAV * | 121.81 USD | 10.02.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 126,900,845 | |
Unit/Share Assets *** | 10,907,879 | |
Trading Information SIX |
YTD Performance | +5.37% |
31.12.2024 - 10.02.2025
31.12.2024 10.02.2025 |
---|---|---|
YTD Performance (in CHF) | +5.77% |
31.12.2024 - 10.02.2025
31.12.2024 10.02.2025 |
1 month | +3.77% |
10.01.2025 - 10.02.2025
10.01.2025 10.02.2025 |
3 months | -0.01% |
12.11.2024 - 10.02.2025
12.11.2024 10.02.2025 |
6 months | -2.95% |
12.08.2024 - 10.02.2025
12.08.2024 10.02.2025 |
1 year | +3.36% |
12.02.2024 - 10.02.2025
12.02.2024 10.02.2025 |
2 years | -1.17% |
10.02.2023 - 10.02.2025
10.02.2023 10.02.2025 |
3 years | -10.92% |
10.02.2022 - 10.02.2025
10.02.2022 10.02.2025 |
5 years | +17.79% |
09.04.2020 - 10.02.2025
09.04.2020 10.02.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 6.53% | |
---|---|---|
UnitedHealth Group Inc | 6.04% | |
Danaher Corp | 5.59% | |
Sanofi SA | 5.11% | |
Boston Scientific Corp | 4.97% | |
Johnson & Johnson | 4.55% | |
Gilead Sciences Inc | 4.00% | |
AstraZeneca PLC | 3.82% | |
Novo Nordisk AS Class B | 3.66% | |
UCB SA | 3.24% | |
Last data update | 31.12.2024 |
TER | 1.37% |
---|---|
TER date | 30.04.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.32% |
SRRI ***
|
|
SRRI date *** | 31.01.2025 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |
GMOs |